BRCA1 and cancer: Consistent with this mechanistic evidence of target engagement and its downstream consequences on DNA integrity, once daily talazoparib dosing demonstrated clinical activity in patients with different cancer histologies and BRCA1/2 mutations, including those who had received prior platinum chemotherapy.